NOT KNOWN FACTUAL STATEMENTS ABOUT TRASTUZUMAB HOW DOES IT WORK

Just about the most beneath-investigated “driving forces” involved in trastuzumab resistance is PTEN. Nagata et al. (2004) described that the lack of PTEN was observed in 36% of HER2-good primary breast tumor specimens from clients with stage IV disorder. Moreover, they also showed that people with PTEN-deficient tumors had remarkably decreased